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Abstract: Poorly water-soluble drugs, such as phenylephrine, offer challenging problems for 
buccal drug delivery. In order to overcome these problems, particle size reduction (to the nano-
meter range) and cyclodextrin complexation were investigated for permeability   enhancement. 
The apparent solubility in water and the buccal permeation of the original phenylephrine coarse 
powder, a phenylephrine–cyclodextrin complex and phenylephrine nanosuspensions were 
  characterized. The particle size and particle surface properties of phenylephrine nanosuspensions 
were used to optimize the size reduction process. The optimized phenylephrine nanosuspension 
was then freeze dried and incorporated into a multi-layered buccal patch, consisting of a small 
tablet adhered to a mucoadhesive film, yielding a phenylephrine buccal product with good dos-
age accuracy and improved mucosal permeability. The design of the buccal patch allows for 
drug incorporation without the need to change the mucoadhesive component, and is potentially 
suited to a range of poorly water-soluble compounds.
Keywords: buccal drug delivery, nanosuspension, solubility, permeation enhancement, 
mucoadhesion
Introduction
The buccal mucosa provides a promising route for the delivery of active   pharmaceutical 
ingredients (APIs). By applying a delivery device to the buccal mucosa, an API can 
be released into the oral cavity for the treatment of a generalized oral condition or 
absorbed through the buccal mucosa for systemic therapy.1 The buccal route offers 
potential advantages in being convenient and painless, and it avoids the impact of the 
harsh gastrointestinal environment and hepatic first-pass metabolism.1,2 However, the 
buccal mucosa represents a significant permeation barrier that limits systemic absorp-
tion of APIs, and adequate absorption from this site requires the API to have reasonable 
solubility in both polar and nonpolar solvents.3,4 Because an increasing number of APIs 
are poorly water-soluble molecules,5 techniques to increase the rate of dissolution are 
required to improve drug absorption through buccal mucosa. Phenylephrine, being 
slightly water soluble and subject to extensive presystemic metabolism in the gut wall 
and the liver,6,7 was investigated as the model drug in this study.
Conventional formulation approaches for water-solubility enhancement include 
co-grinding with surfactants,8,9 formation of solid dispersions,10,11 and inclusion com-
plexes with hydrophilic cyclodextrins.12–15 In addition to these techniques, particle 
size reduction to the nanometer range has also been utilized.16–18 For instance, the 
use of a nanosuspension was able to overcome the low/erratic absorption problem 
associated with poorly water-soluble drugs after peroral,19,20 transdermal,21 ocular,22 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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or pulmonary23 administration. The low particle radius and 
enlarged surface area of nanosuspensions lead to a consequent 
improved rate of dissolution that can contribute to increased 
drug absorption.24–27 In this study, the potential benefits of 
two techniques (formation of cyclodextrin complexes and 
particle size reduction) in improving the buccal transmucosal 
permeability of phenylephrine were assessed.
To allow the administration of a nanosuspension via 
the buccal mucosa, appropriate delivery devices to load the 
nanosuspensions are required. The preparation process of 
traditional buccal devices often requires dispersion of the 
API within the polymeric matrix,28,29 which may result in a 
growth in particle size. In order to overcome this problem, 
a microreservoir based buccal patch was developed. A phe-
nylephrine nanosuspension was incorporated into the buccal 
patch and evaluated for dosage accuracy and drug perme-
ability to confirm the applicability of the improved buccal 
patch for delivering poorly water-soluble APIs.
Material and methods
Materials
Phenylephrine was purchased from ABCR Gmbh & Co. 
KG (Baden-Württemberg, Germany). Polymers used in the 
preparation of mucoadhesive films were hydroxypropylm-
ethylcellulose (HPMC) 2910 (Sigma-Aldrich Co, St Louis, 
MO) and Carbopol 934P (Lubrizol, Wickliffe, OH). Other 
excipients used in the preparation of buccal patches were 
cross-linked polyvinylpyrrolidone (PVPP) (Fluka, Sigma-
Aldrich Co, St Louis, MO), sodium starch glycolate (CMS 
Na) (JRS Pharma Gmbh & Co KG, Baden-Württemberg, 
Germany), polyethylene glycol (PEG) 6000 (ACE Chemi-
cal Company, South Australia, Australia), and aerosil R974 
(Degussa, Victoria, Australia). Microcrystalline cellulose, 
lactose, sorbitol, and mannitol used in the preparation of 
microtablets were generous gifts from Mayne Pharma Inter-
national Pty Ltd (South Australia, Australia). Other materials 
used in the preparation and evaluation were PEG 300 (Ph Eur 
Grade, Sigma-Aldrich Chemie Gmbh, Bavaria, Germany), 
dibutyl sebacate (Aldrich, Sigma-Aldrich Co, St Louis, MO), 
ethocel standard 20 (Ethyl cellulose) (Dow Chemical Ltd, 
New South Wales, Australia), and citric acid (Ward Mck-
enzie Pty Ld, Victoria, Australia). Water was obtained from 
a Milli-Q purification system (Millipore Australia Pty Ltd, 
New South Wales, Australia), and all other chemicals were 
of analytical grade and were used as received.
Pig cheek tissue was obtained from a local abattoir within 
1 hour after slaughter and transported to the laboratory in 
ice-cold Krebs Bicarbonate Ringer (KBR) buffer (115.5 mM 
NaCl, 4.2 mM KCl, 21.9 mM NaHCO3, 12.2 mM glucose, 
4.0 mM HEPES, 1.2 mM MgSO4⋅7H2O, 2.5 mM CaCl2⋅2H2O, 
and 1.6 mM NaH2PO4⋅2H2O, pH 7.4). The mucosal epithe-
lium was carefully separated from the underlying tissues 
using forceps and surgical scissors. The isolated mucosal 
epithelium was mounted between the donor and the receptor 
compartment of Franz diffusion cells (specially designed, 
receptor volume: 15 mL, diffusion area: 1.77 cm2) filled 
with KBR buffer, and equilibrated at 37°C for 1 hour prior 
to use.
hPLc analysis of phenylephrine
Analysis of phenylephrine in diffusion medium was per-
formed after chromatographic separation on a reversed 
phase C18 column (Phenomenex® Luna® 5 µm C18 (2), 
150 × 4.6 mm, Torrance, CA). The HPLC system comprised a 
chromatography pump and a UV variable wavelength UV-vis 
detector set to 260 nm. The mobile phase was methanol-water 
(50:50%, v/v) and 1-octane sulfonic acid (1.1%, w/v), appar-
ent pH 6.9. The flow rate was 1.0 mL/minute, the injection 
volume was 10 µL, and the retention time of phenylephrine 
was 5.1 minutes.
characterizations of original and 
modified phenylephrine
Assessment of apparent solubility in water
The known excess of phenylephrine was added to 10 mL 
of Milli-Q water. The sample was rotated at 20 rpm in a 
thermostatic chamber (37.0 ± 0.5°C) for 72 hours and centri-
fuged at 4,000 rpm for 10 minutes. The supernatant was then 
filtered through Acrodisc® Syringe Filters (0.45 µm Supor® 
membrane, Paul Co. Ltd., Ann Arbor, MI) and analyzed by 
HPLC analysis as described above, from which the apparent 
solubility was determined.
Particle size and zeta potential assessment
The measurement of particle size, polydispersity index (PDI) 
and zeta potential was performed using a Malvern Zetasizer 
Nano ZS (Malvern Instruments, Worcestershire, UK) with 
manufacturer’s software.
Permeability assessment
Permeability was measured with porcine buccal mucosal 
epithelium in Franz diffusion cells. A 2 mg dose of phe-
nylephrine, in the form of phenylephrine solution (3.37, 
5.05, 9.91 mg/mL) or modified phenylephrine, was loaded 
onto the mucosal surface in the donor compartment. Samples 
(0.1 mL) were removed from the receptor compartment International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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through the sampling arm at fixed intervals over 4 hours 
and replaced with fresh KBR buffer (0.1 mL). Samples were 
filtered through Acrodisc® Syringe Filters (0.45 µm Supor® 
membrane, Paul Co. Ltd., Ann Arbor, MI) and analyzed by 
HPLC to detect the amount of phenylephrine reaching the 
receptor compartment, from which cumulative permeation 
(as percentage of loading dose) was calculated. All experi-
ments were conducted with 6 replicates, and results are given 
as mean ± standard deviation (SD). Steady-state flux (Js) 
was calculated using Equation 1, where dQ is the amount of 
phenylephrine moving through the mucosa during time dt, 
and A is the diffusional area (1.77 cm2).
 
Js
dQ
Ad t
=
()
  (1)
Preparation of phenylephrine-hydroxypropyl-β-
cyclodextrin complex (Pe-hPβcD)
An aqueous 10% (w/v) hydroxypropyl-β-cyclodextrin 
(HPβCD) solution was prepared. The solid complex was 
prepared by adding methanolic phenylephrine (10%, w/v, 
2 mL) drop wise into the HPβCD solution (10 mL). The clear 
solution was cooled to −80°C within 2 hours and freeze-dried 
(Lyph · Lock® Systems, Labconco Co., Kansas City, MI) to 
form phenylephrine-HPβCD complex (PE-HPβCD).
Preparation of phenylephrine nanosuspension
A nanosuspension of phenylephrine (NPE1) was pre-
pared by milling in a mannitol aqueous solution (50%, 
w/v) using grinding balls (diameter: 1 mm, zirconium 
oxide) in a micromill (Fritsch®, Planetary Micro Mill 
PULVERISETTE 7 premium Line, Rhineland-Palatinate, 
Germany) with a batch size of 10 mL. A second nanosuspen-
sion (NPE2) was prepared by high-pressure homogenization 
of NPE1   (Avestin® EmulsiFlex-C50 Homogenizer, Baden-
Württemberg, Germany) under a pressure of 500 to 1000 
bar for 30 minutes with a batch size of 10 mL. The milling 
time and the nanosuspension composition were optimized 
by in vitro evaluations of apparent solubility, particle size, 
and transmucosal permeability.
Incorporation of nanosuspension  
into buccal patches
Formation of dry nanosuspension
The optimized nanosuspension was prepared, cooled to 
−80°C within 2 hours, and freeze dried to form phenyleph-
rine dry nanosuspension (DNPE). A known amount of 
DNPE was dissolved in Milli-Q water, vortexed and cen-
trifuged at 4,000 rpm for 10 minutes. The supernatant was 
filtered through Acrodisc® Syringe Filters (0.45 µm Supor® 
  membrane, Paul Co. Ltd., Ann Arbor, USA) and assessed 
by HPLC to determine the content of phenylephrine per unit 
weight of DNPE (%, w/w).
Preparation of phenylephrine-containing buccal patch
The buccal patch, based on a platform technology developed 
by Rao et al,30 consists of a microreservoir, specifically 
a microtablet, bound to a bi-layered mucoadhesive film 
(Figure 1). The two components were prepared separately. 
The final formulation incorporating coarse phenylephrine 
powders (PMT1) or phenylephrine dry nanosuspension 
(PMT2) within the microtablet was prepared by direct manual 
attachment of the medicated microtablet to the mucoadhesive 
layer with the aid of ethanol as a moistening agent.
Polymer solutions were prepared by dissolving 4.6% (w/v) 
polymers (Carbopol 934P:HPMC 2910 10:1.5) and 1.6% 
(v/v) plasticizer (PEG 300) in 60% ethanol solution under 
overhead stirring at 600 rpm for 30 minutes. This solution 
was transferred to glass plates; the thickness of the solution 
was controlled to 3.5 mm and the surface of the solution was 
flattened using a spatula; the solution was then dried in an oven 
(60°C) to form the mucoadhesive layer. For the ethylcellulose 
layer, 5% (w/w) ethylcellulose ethanol solution containing 
0.4% (w/v) of dibutyl sebacate was sprayed via a nozzle onto 
one side of the mucoadhesive layer (2 µL/cm2) and allowed to 
dry. The patch was then cut with a circular punch (diameter: 
20 mm) and stored in an airtight container until required.
The microtablet was prepared using the direct compres-
sion technique. The appropriate amount of drug and excipi-
ents (details given in Table 1) were mixed   homogenously, 
passed through a #60 (US standard) screen and then 
  compressed in a 7 mm diameter die, using a Korsch XP-1 
tablet press (Korsch AG, Berlin, Germany).
ex vivo drug permeability assessment
Drug permeability assessments of the phenylephrine patch 
were assessed using Franz diffusion cells. Each patch was 
clamped between the donor and the receptor compartment 
with the support of porcine buccal mucosa (prepared as 
described above and equilibrated for 1 hour in KBR   buffer). 
The receptor compartment was filled with dissolution 
Micro-reservoir containing phenylephrine
Mucoadhesive layer
Backing layer
Figure 1 Phenylephrine-containing buccal patch.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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medium (KBR buffer) and maintained at 37°C with constant 
stirring by a magnetic stirrer. The cumulative amount of drug 
reaching the receptor at each time point was determined by 
removing aliquots (0.1 mL) through the sampling arm at fixed 
intervals and immediately replacing the same volume of dis-
solution medium. Samples were filtered through   Acrodisc® 
Syringe Filters with 0.45 µm Supor® membrane and ana-
lyzed by HPLC. All experiments with either type of buccal 
mucoadhesive patches were conducted in six replicates, and 
the results were described as mean ± SD.
Results
Incorporating phenylephrine as a hydroxypropyl-β-
cyclodextrin complex (PE-HPβCD) was able to increase its 
apparent solubility from 10.37 ± 0.17 mg/mL for unmodified 
phenylephrine to 13.82 ± 0.35 mg/mL for PE-HPβCD com-
plex (P , 0.05). Table 2 shows the apparent solubility of a 
range of phenylephrine nanosuspensions following different 
size reduction processes. Apparent solubility did not increase 
constantly as the milling continued, and a 10-minute milling 
process yielded nanosuspensions with the highest apparent 
solubility (14.12 mg/mL, NPE1, Table 2). The application 
of high-pressure homogenization to the milled sample fur-
ther improved apparent solubility to 17.18 mg/mL (NPE2, 
Table 2). Apparent solubility of the final phenylephrine dry 
nanosuspension (DNPE), obtained after freeze drying NPE2, 
was 18.31 mg/mL.
Phenylephrine coarse powders were relatively large   particles 
(.1 µm) and required milling and high-pressure homog-
enization processes to form phenylephrine   nanosuspensions. 
Table 3 shows particle size and particle surface properties 
of the different nanosuspensions. NPE1 presented an aver-
age particle size of 832.4 nm, the particle size of NPE2 was 
500.3 nm, and DNPE showed a particle size of 216.8 nm 
(Table 3). The PDI, a parameter used to measure the width of 
particle distribution, was below 0.5 for each phenylephrine 
nanosuspension (Table 3), which indicates the relatively nar-
row particle size distribution.16 The zeta-potential value, which 
reflects surface properties of nanosized products, was −26.0, 
−16.7 and −15.1 mV for NPE1, NPE2 and DNPE, respectively 
(Table 3), which fell within the range of −15 mV to −30 mV 
for well-stabilized nanosuspensions.31
Using porcine buccal mucosal tissue, a linear relationship 
was observed between the transmucosal flux and the donor 
concentration of phenylephrine (R2 = 0.9999, Figure 2). 
Transmucosal flux of phenylephrine solution (9.911 mg/mL) 
was 3.27 ± 0.41 × 10–4 mg/cm2 · min, meaning that for 2.5 mg 
of phenylephrine to be delivered through an area of approxi-
mately 3 cm2, more than 40 hours would be required.
Figure 3 shows that the PE-HPβCD complex and the 
phenylephrine nanosuspensions achieved higher perme-
ability than the unmodified phenylephrine. PE-HPβCD 
and NPE1 had comparable permeability, with more than 
0.2 mg of phenylephrine permeating through the mucosa 
over 240 minutes. Transmucosal flux was 7.78 ± 0.42 × 10–4 
mg/cm2 · min and 7.32 ± 0.36 × 10–4 mg/cm2 · min for 
PE-HPβCD and NPE1, respectively. For NPE2 and 
DNPE, more pronounced permeation enhancement was 
Table 1 compositions of phenylephrine-containing microreservoirs (mg per microtablet)
Microtablet Lactose Mannitol PVPP CMS Na PEG 6000 Aerosil Phenylephrine DNPE
PMT1 11.25 15 1.875 2.625 10.5 2.25 2.5
PMT2 11.25 12.5 1.875 2.625 10.5 2.25 5.0a
Note: aequivalent to approximately 2.5 mg phenylephrine.
Abbreviations: Peg, polyethylene glycol; PMT1, microtablet-incorporating coarse phenylephrine powders; PMT2, microtablet-incorporating phenylephrine dry nanosuspension; 
PVPP, polyvinylpyrrolidone; cMs Na, sodium starch glycolate; DNPe, phenylephrine dry nanosuspension.
Table  2  Preparation  process  and  apparent  solubility  of 
nanosuspensions
Media milling  
(minutes)
Apparent solubility   
after 72 hours  
(mg/mL)
NPe1 0 10.37
5 12.54
10 14.12a
15 13.91
20 13.44
NPe2 10b 17.18
Notes: aselected for further studies; bhomogenized for 30 minutes following the 
milling process.
Abbreviations:  NPe1,  phenylephrine  nanosuspension  prepared  by  milling  in  a 
mannitol aqueous solution; NPe2, phenylephrine nanosuspension prepared by high 
pressure homogenization of NPe1.
Table 3 Particle size, polydispersity index (PDI) and zeta-potential 
of coarse powder or nanosuspensions of phenylephrine
Particle size (nm) PDI Zeta-potential (mV)
coarse .1000
NPe1 832.4 0.294 −26.0
NPe2 500.3 0.333 −16.7
DNPe 216.8 0.416 −15.1
Abbreviations:  NPe1,  phenylephrine  nanosuspension  prepared  by  milling  in  a 
mannitol aqueous solution; NPe2, phenylephrine nanosuspension prepared by high 
pressure homogenization of NPe1; DNPe, phenylephrine dry nanosuspension.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Both PMT1 and PMT2 were found to perform   appropriately 
as potential delivery systems, with acceptable dosage 
accuracy, containing 2.47 ± 0.05 mg and 2.42 ± 0.01 mg 
of phenylephrine, respectively. The permeability of phe-
nylephrine from the patches varied, with significantly higher 
drug permeability observed for PMT2 (Figure 4). While a 
maximum of 5% of phenylephrine from PMT1 permeated 
through the mucosa over a period of 180 minutes, this was 
significantly exceeded by the PMT2 patches. For PMT2, the 
permeation percentage (as a function of loading dose) was 
5.14 ± 1.01% at 60 minutes, 9.14 ± 2.02% at 120 minutes, 
and 14.99 ± 2.39% at 240 minutes (Figure 4).
Discussion
Buccal drug delivery provides a promising route for the 
administration of APIs where avoidance of gastrointestinal 
degradation and hepatic first-pass metabolism is desired. 
However, efficient systemic drug delivery through buccal 
mucosa requires suitable water solubility for initial dissolu-
tion of the API and adequate transmucosal permeability to 
ensure movement of the API into the bloodstream. For poorly 
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Figure 2 Transmucosal flux of phenylephrine through the porcine buccal mucosa 
versus the concentration of phenylephrine solution.
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achieved, with an approximately 4-fold increase in the 
transmucosal flux (2.06 ± 0.36 × 10–3 mg/cm2 · min for 
NPE2 and 1.58 ± 0.22 × 10–3 mg/cm2 · min for DNPE 
versus 3.27 ± 0.41 × 10–4 mg/cm2 · min for unmodified 
phenylephrine).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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water-soluble compounds, techniques to increase water 
solubility or the rate of dissolution are required to increase 
buccal absorption.
Solubility is generally defined as a compound-specific 
constant depending only on the temperature and the crystalline 
structure. However, the rate of dissolution and thus the appar-
ent solubility of phenylephrine were remarkably improved by 
the formation of a hydroxypropyl-β-cyclodextrin complex 
with phenylephrine or the development of a phenylephrine 
nanosuspension. The increase in apparent solubility then 
brought a significant increase in transmucosal permeation. 
A 30% increase in apparent solubility by cyclodextrin compl-
exation led to a doubling of transmucosal flux through porcine 
buccal mucosa, and an 80% increase in apparent solubility 
via nanosuspension was accompanied by approximately a 
4-fold increase in the transmucosal flux. It is postulated that 
with the increase in apparent solubility, more dissolved drug 
is presented to the porcine buccal mucosal surface, resulting 
in a higher concentration gradient across the membrane. Since 
phenylephrine permeates through buccal mucosa via passive 
diffusion (confirmed by the linearity between transmucosal 
flux and donor concentration, Figure 2), the increase in con-
centration gradient across the membrane contributed to the 
improved permeability of phenylephrine. Therefore, cyclo-
dextrin inclusion and particle size reduction to the nanometer 
range were confirmed as two effective techniques to improve 
buccal transmucosal permeability of phenylephrine via 
increasing apparent solubility. The feature of mucosal adhe-
siveness and the consequent prolonged retention at mucosal 
surface further suggests the use of nanosuspensions for buccal 
drug delivery may be a promising technique.
Though the development of nanosuspensions may solve 
the problem of low water solubility and result in enhanced 
permeation, it is challenging to incorporate nanosuspensions 
into devices for buccal drug delivery in terms of preserv-
ing the nanosize feature. Preparation of traditional buccal 
devices, typically buccal films, often requires the suspension/
dissolution of drug and polymers in an aqueous media,32,33 
which will destroy the nanosize feature of nanosuspen-
sions and lead to an increase in particle size. The improved 
microreservoir-based buccal patch developed in this study 
consists of a medicated microtablet bound to a mucoadhesive 
film. The patch enables drug incorporation without direct 
contact between drug and mucoadhesive polymers, so that 
drug can be directly released to the mucosal surface without 
being influenced by the polymeric matrices. This new type of 
buccal patch has been previously characterized with at least a 
2-hour retention time at the human buccal mucosa and with 
the capability to deliver APIs without potential drug loss into 
the oral cavity.30 Incorporation of phenylephrine dry nano-
suspension into the patch yielded products with satisfactory 
dosage accuracy. In addition, improved drug permeability 
was achieved with the patch containing phenylephrine nano-
suspension, suggesting that the microreservoir based buccal 
patch may provide a prototype buccal device to deliver poorly 
water-soluble APIs through buccal mucosa.
Conclusion
The challenging problems associated with delivering poorly 
water-soluble APIs through the buccal mucosa can be 
overcome, at least in part, by water solubility enhancement 
techniques. Cyclodextrin complexation and size reduction 
to nanometer range were found to be two techniques able 
to increase buccal absorption of phenylephrine with more 
pronounced enhancement achieved with nanosuspensions. 
Incorporating the phenylephrine nanosuspension into the 
microreservoir based buccal patch resulted in a satisfac-
tory product, with uniform drug content and relatively 
high   permeability. The microreservoir based buccal patch 
allowed successful incorporation of nanosuspensions, and 
could potentially be utilized for the delivery of a range of 
poorly soluble APIs.
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